Novavax Inc. (NVAX) exhibits 93.5% gross margins and 85.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 3.3x enterprise multiple and 4.8% implied options volatility.
Sustained 93.5% gross profitability converts into 40.3% operating margin and 85.0% ROIC, outpacing sector cost of capital.
ROIC: 85.0% // GM: 93.5%YoY revenue trajectory of +64.7% paired with -14.17% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +64.7% // FCF YLD: -14.17%Altman Z-Score of 0.20 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 5/9Trading at 3.9x trailing P/E (3.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 3.9x // EV/EBITDA: 3.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $10.47 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 39.2% net margins.
NET MARGIN: 39.2% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NVAX & activate live FRED threshold breach alerts.